Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Non-small Cell Lung Cancer

In brief

This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.

Key facts

Study ID
NCT03631199
Run by
Novartis Pharmaceuticals
People needed
673
Starts
2018-12-21
Expected to finish
2026-01-26
Last updated by the study team
2026-06-17

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.